AIDEN, the METABOLIC FATTY LIVER DISEASE CONSORTIUM, founded in 2022, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of fatty liver disease, and to providing education to all those interested in MAFLD and to be the official body to represent APASL on any matters related to fatty liver disease.

  The consortium comprises 146 key opinion leaders from 22 countries/administrative regions in the Asia Pacific region. We welcome all with such intent to join this APASL MAIDEN initiative.

MAIDEN engages globally with all stakeholders in the field of hepatology, worldwide. Our aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in this field. We advocate for the benefit of patients and advise Asian and national health authorities.

Thankfully, there is no dearth of patients, clinical databases, and bench-to-bedside research across the globe to provide unique opportunities for collaboration and for knowledge gain. This then is the intent of the consortium, to bring together clinicians, researchers and patient representatives to tackle the burden of MAFLD. MAIDEN will run topical conferences, webinars, and related educational meetings. Our journals, the Hepatology international provides an international forum for the publication of original articles, reviews, and letters to the Editor, describing the latest science in hepatology.

Many ways, one aim: A world in which no one suffers from the consequences of MAFLD.

The overarching principles of APASL MAIDEN are a patient-oriented focus, transparency and equity, credible data sharing and professional communication. The consortium in its charter will uphold and embed an evidence-based scientific approach that we expect will be acceptable to the 5 P’s (Patients, Physicians, Pharma, Policy makers and the Public).






  • Further the science and practice of Hepatology as it pertains to MAFLD in the APASL region

  • Engage with sister societies on fatty liver disease research and clinical practice

  • Establish a forum dialogue and for research collaboration

  • Enhance the role of APASL as a key driver of fatty liver disease research in the region and globally

  • Contribute to clinical trials for patients in our region

  • Provide educational opportunities and resources on fatty liver disease for our patients and their families, policy makers and healthcare providers